Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer
Julia Pannhausen(Integrated Oncology (United States)), Roman Nawroth(TUM Klinikum)
Cited by 3
Related Papers
S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
|PLoS ONE|2011|92
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
|PLoS ONE|2018|51
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
|British Journal of Cancer|2014|38
Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
|Journal of Experimental & Clinical Cancer Research|2019|34
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
|Journal of Personalized Medicine|2021|14